Based on the heterogeneous nature of colorectal cancer, to identify predictive biomarkers for VEGF signaling inhibitors may potentially broaden the clinical impact of these agents and might even distinguish the clinic application of each agent. This evidence concerns the gene VEGFA and colorectal cancer.